Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

NCT06071845 · View on ClinicalTrials.gov ↗

Study Summary

This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minimally invasive, non-endoscopic, encapsulated sponge sampling device to identify BE/EAC biomarkers that indicate whether a patient should undergo diagnostic endoscopy. The OGE test is a simple and cost effective screening method that may lower barriers to widespread adoption of BE screening in at risk patients, resulting in increased and earlier detection of BE/EAC.

Interventions

  • DEVICE Cytosponge Procedure
  • DIAGNOSTIC_TEST Endoscopic Assessment

Study Locations (5)

Arizona

  • Mayo Clinic — Scottsdale

Florida

  • Mayo Clinic in Florida — Jacksonville

Illinois

  • Northwestern University — Chicago

Minnesota

  • Mayo Clinic in Rochester — Rochester

New York

  • Long Island Jewish Medical Center | Northwell Health — New Hyde Park

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-10-16
Est. Completion 2026-06-01
Phase NA

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06071845

The ClinicalTrials.gov registry entry for NCT06071845 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions — of which Cytosponge Procedure is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06071845 reports 5 study locations spanning 5 distinct geographic areas — top geographies include Arizona, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06071845 about?

NCT06071845 is a clinical study titled "Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples". This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (E...

What is the current status of trial NCT06071845?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-10-16. Estimated completion is 2026-06-01.

What conditions does trial NCT06071845 study?

This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06071845?

The interventions under investigation include: Cytosponge Procedure (DEVICE), Endoscopic Assessment (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06071845?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06071845 being conducted?

This trial has 5 study locations across Arizona, Florida, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial